Drug Approval | May 01, 2025
USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility
The Subsidiary has received one inspectional observation in Form 483
The Subsidiary has received one inspectional observation in Form 483
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
This unit will focus on the manufacturing of health and wellness equipment
The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024
The plant will have installed production capacity of 3,120 MT/month
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
The products will be manufactured in Goa India and marketed & distributed in Australian markets
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Subscribe To Our Newsletter & Stay Updated
